ライフサイエンスコーパス: somatostatin receptor

1 could equally sequester G-proteins from the somatostatin receptor.

2 Galpha(oB) = Galpha(i2) > Galpha(oA) for the somatostatin receptor.

3 y of novel ligands for the G-protein-coupled somatostatin receptor.

4 tinguishable from response to the endogenous somatostatin receptor.

5 a category of NETs that does not express the somatostatin receptor.

6 ind and transduce human 293 cells expressing somatostatin receptors.

7 ence of ZnCl(2) and after blockade of type-2 somatostatin receptors.

8 , which express both bcl-2 messenger RNA and somatostatin receptors.

9 cells transfected with the five known human somatostatin receptors.

10 rent modulation by the alpha2-adrenergic and somatostatin receptors.

11 ailable to couple to alpha(2)-adrenergic and somatostatin receptors.

12 LC-1) that is sequentially homologous to the somatostatin receptors.

13 selectivity when evaluated against the other somatostatin receptors.

14 pioid, alpha2-adrenergic, M2 muscarinic, and somatostatin receptors.

15 GH12C1 and F4C1 cells, which lack endogenous somatostatin receptors.

16 All cells have inhibitory somatostatin receptors.

17 docrine tumors express different subtypes of somatostatin receptors.

18 r (NOP), MCHR1, both orexin receptors (ORX), somatostatin receptors 1 and 2 (SSTR1, SSTR2), kisspepti

19 The binding affinity of somatostatin receptors 1 through 5 was evaluated in all

20 sodium iodide symporter (hNIS) and the human somatostatin receptor 2 (hSSR2) in the vaccinia-based OV

21 for quantitating 125I-SS14 binding to human somatostatin receptor 2 (hSST2) have been developed.

22 e gastrin-releasing peptide receptor (GRPR), somatostatin receptor 2 (SSTR2), and chemokine C-X-C mot

23 ntified between mu opioid receptor (MOR) and somatostatin receptor 2 (SSTR2).

24 Meningiomas are known to express somatostatin receptor 2 (SSTR2).

25 One may therefore generalize that somatostatin receptor 2 antagonists are sensitive to rad

26 ere the lowest-affinity radioligands, with a somatostatin receptor 2 binding affinity up to 60 times

27 bles detection of meningioma tissue based on somatostatin receptor 2 expression.

28 class A G protein-coupled receptors: SSTR2 (somatostatin receptor 2), CHRM2 (cholinergic receptor, m

29 7)Lu-DOTATATE), where the latter targets the somatostatin receptor-2.

30 protein-coupled receptors (GPCRs), including somatostatin receptor 3 (Sstr3) and serotonin receptor 6

31 hese dynamics, we imaged single molecules of Somatostatin Receptor 3 (SSTR3, a GPCR) and Smoothened (

32 two G protein-coupled receptors (GPCRs)-the somatostatin receptor 3 and rhodopsin.

33 d P1s stretching 1.1 Mb from D15Mit30 to the somatostatin receptor 3 gene is reported, and the DNA in

34 Finally, the ciliary targeting signal of somatostatin receptor 3 needs to be directly recognized

35 , we demonstrate that, unlike the seven-span somatostatin receptor 3 or the leptin receptor that inte

36 e ciliary membrane protein and BBSome cargo, somatostatin receptor 3, and significantly reduces axone

37 ium enrichment of a chimera of rhodopsin and somatostatin receptor 3, where the dual Ax(S/A)xQ ciliar

38 A somatostatin receptor 5 antagonist, which blunts inhibit

39 rement of [35S]GTPgammaS binding mediated by somatostatin receptor activation in the presence of diff

40 th DAMGO did not affect the Kir3 response to somatostatin receptor activation.

41 adenoviral vector encoding the human type 2 somatostatin receptor (Ad5-CMVhSSTr2).

42 roof of principle studies with octreotide, a somatostatin receptor agonist, demonstrated it to be bet

43 a TGR5 antagonist alone or concurrently with somatostatin receptor agonists represents a potential th

44 eurons, alpha 2 adrenoceptors, mu-opioid and somatostatin receptors all activate the same potassium c

45 E is similar to that of other (68)Ga-labeled somatostatin receptor analogs.

46 a combination of SBI-115 and pasireotide, a somatostatin receptor analogue.

47 ptides which possess a high affinity for the somatostatin receptor and contain a chelator for the rad

48 med to characterize the interaction with the somatostatin receptor and the intracellular fate of 64Cu

49 g for 3 receptor systems--steroid receptors, somatostatin receptors, and growth factor receptors-are

50 Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already

51 backbone N-methylation approach to a potent somatostatin receptor antagonist series using the antago

52 ming developments in PRRT include the use of somatostatin receptor antagonists and alpha-emitting rad

53 In COS-7 cells, all five cloned somatostatin receptors are coupled via inhibitory G prot

54 Only Ad5-CMVhSSTr2-injected tumors expressed somatostatin receptors, as determined by immunohistochem

55 ing somatostatin and is suitable for imaging somatostatin receptor-bearing tumors.

56 (68)Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors.

57 ecause these cells express all five types of somatostatin receptors before the initiation of their mi

58 tives led to structural perturbations of the somatostatin receptor-binding sequence relative to the R

59 de, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding

60 stimulation by paracrine inhibition, because somatostatin receptor blockade potently stimulated gluca

61 ch include binding to five recombinant human somatostatin receptors carried out in two independent la

62 At early developmental stages somatostatin receptors coupled predominantly to the curr

63 Thus, somatostatin receptor coupling to Ca2+ channels persiste

64 tatin analogues (e.g. sandostatin) acting at somatostatin receptors, CTAP which binds specifically to

65 Five different subtypes of somatostatin receptors, designated sst1-5, have been ide

66 Activation of somatostatin receptors endogenous to HEK293 cells or kap

67 To extend this concept, we have developed a somatostatin receptor-enhanced green fluorescent protein

68 l neuroendocrine tumors (NETs) overexpresses somatostatin receptors, especially the sst2 subtype.

69 In vitro uptake was studied in somatostatin receptor-expressing CA20948 and megalin or

70 matostatin analogs used for the diagnosis of somatostatin receptor-expressing neuroendocrine tumors (

71 cessfully applied for imaging and therapy of somatostatin receptor-expressing neuroendocrine tumors u

72 T/CT provides information on the location of somatostatin receptor-expressing tumors.

73 ons for diagnosis, staging, and restaging of somatostatin receptor-expressing tumors.

74 e for either tracer for PET/CT evaluation of somatostatin receptor-expressing tumors.

75 hed changes in presynaptic dopamine, whereas somatostatin receptor expression remained constant.

76 Tumors were frozen and evaluated for somatostatin receptor expression using fluorescein-label

77 h metastatic neuroendocrine tumors with high somatostatin receptor expression were included.

78 Somatostatin receptor expression, which was not a previo

79 ace levels of three different members of the somatostatin receptor family (SSTR) which have natural d

80 Meningiomas express members of the somatostatin receptor family.

81 Allelic variation in the five somatostatin receptor genes (Smstr) could contribute to

82 e of a cocktail of 3 radioligands binding to somatostatin receptors, GLP-1 receptors, and GIP recepto

83 Somatostatin receptors have been identified in a variety

84 mpetent adenovirus encoding the human type 2 somatostatin receptor (hSSTr2) and the herpes simplex vi

85 se of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractiv

86 In this study, we selected the somatostatin receptor imaging agent DOTATOC as the found

87 Somatostatin receptor imaging has recently been introduc

88 intigraphy to evaluate the potential role of somatostatin receptor imaging in inflammatory bowel dise

89 Somatostatin receptor imaging is a valuable tool in the

90 been posed as a potential source of error in somatostatin receptor imaging through interference with

91 Somatostatin receptor imaging with (68)Ga-DOTATATE PET/C

92 ementary argument for replacing SPECT by PET somatostatin-receptor imaging.

93 r sensory cilia, inhibited enrichment of the somatostatin receptor in primary cilia.

94 Despite the lack of significant somatostatin receptors in the affected bowel, an unexpec

95 The expression of somatostatin receptors in the stimulated adrenals may be

96 octreotide scintigraphy, which binds to the somatostatin receptors in the tumor.

97 Activation of somatostatin receptors increases the rate of granule cel

98 adrenergic, prostaglandin E(2), M(1)Ach, and somatostatin receptors induced arrestin-2-GFP redistribu

99 A high density of somatostatin receptors is also present in most intestina

100 ns use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope wi

101 (68)Ga-labeled somatostatin receptor ligand PET imaging has recently be

102 A somatostatin receptor ligand that is easily radiolabeled

103 ",N'''-tetraacetic acid (TETA)-octreotide, a somatostatin receptor ligand, inhibits the growth of CA2

104 tial studies in the United States focused on somatostatin receptor ligands.

105 se delivered by (18)F-FDG- or (68)Ga-labeled somatostatin receptor ligands.

106 rodihydroxyphenylalanine (FDOPA), and (68)Ga somatostatin-receptor ligands in NETs has been expanding

107 er RNA was attached to Tyr(3)-octreotate for somatostatin receptor-mediated intracellular delivery.

108 gate 1 was taken up by Mec-1 cells through a somatostatin receptor-mediated mechanism.

109 ide sequence of the gene for the fifth mouse somatostatin receptor (msst5).

110 atostatin receptor-positive cells but not in somatostatin receptor-negative cells.

111 yed significantly higher binding affinity to somatostatin receptors on CA20948 rat pancreatic tumor m

112 Somatostatin receptor PET tracers such as [(68)Ga-DOTA,1

113 These studies incorporate the use of somatostatin receptor-positive AR42J rat pancreatic tumo

114 sing therapeutic candidate for patients with somatostatin receptor-positive cancer.

115 eotide binding to DNA increased over time in somatostatin receptor-positive cells but not in somatost

116 r moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of

117 111In-DTPA-octreotide after it localizes in somatostatin receptor-positive tissues and sought to det

118 is due to the selective uptake of AN-238 by somatostatin receptor-positive tissues.

119 (Y3-TATE) improved uptake of the peptide in somatostatin receptor-positive tissues.

120 They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 n

121 ing results of (86)Y-CHX-A''-octreotide in a somatostatin receptor-positive tumor-bearing rat model a

122 introduced not only for the localization of somatostatin receptor-positive tumors but also for selec

123 predict that both are effective for imaging somatostatin receptor-positive tumors in vivo.

124 ty profile in children and young adults with somatostatin receptor-positive tumors.

125 lus 29% minor response rate in patients with somatostatin receptor-positive tumors.

126 a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.

127 opharmaceutical for targeted radiotherapy of somatostatin receptor-positive tumors.

128 T patients from a group of 367 patients with somatostatin receptor-positive tumors.

129 tate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tum

130 raacetic acid) and PET can be used to detect somatostatin-receptor-positive tumors in humans.

131 e1-octreotide (OC) was developed for imaging somatostatin-receptor-positive tumors using conventional

132 , subtype-selective agonists for each of the somatostatin receptors provides a direct approach to def

133 eptor-expressing neuroendocrine tumors using somatostatin receptor radioligands.

134 Agonists for serotonin, adenosine, and somatostatin receptors reliably activated a potassium-se

135 s within the third intracellular loop of the somatostatin receptor replaced the third intracellular l

136 were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) before treatmen

137 ents had negative imaging studies in the pre-somatostatin receptor scintigraphy (SRS) era, and 23 pat

138 Somatostatin receptor scintigraphy (SRS) has a high sens

139 Somatostatin receptor scintigraphy (SRS) is being increa

140 1In-DTPA-D-Phe1]-octreotide was approved for somatostatin receptor scintigraphy (SRS) of gastroentero

141 Only patients with negative conventional and somatostatin receptor scintigraphy (SRS) results were st

142 )I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pe

143 brain, preferably with MR, together with the somatostatin receptor scintigraphy (SRS), in each clinic

144 Tc-hydrazinonicotinamide (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) SPECT/CT, (68

145 elective angiography, and bone scanning) and somatostatin receptor scintigraphy done using [111In-DTP

146 s, by angiography in 40% of patients, and by somatostatin receptor scintigraphy in 70% of patients.

147 ocol with the commonly used 3-d protocol for somatostatin receptor scintigraphy in patients with gast

148 Somatostatin receptor scintigraphy is the single most se

149 neoplasm patients undergoing restaging with somatostatin receptor scintigraphy on a modern SPECT/CT

150 results of all other tests were added to the somatostatin receptor scintigraphy results, tumors were

151 MRI, ultrasound; if unclear, angiography and somatostatin receptor scintigraphy since 1994 to determi

152 , or ultrasound; if unclear, angiography and somatostatin receptor scintigraphy since 1994.

153 Somatostatin receptor scintigraphy was as sensitive as a

154 Somatostatin receptor scintigraphy was as sensitive as t

155 Somatostatin receptor scintigraphy was performed on a pa

156 Somatostatin receptor scintigraphy was significantly bet

157 phy were positive in 28%, and the results of somatostatin receptor scintigraphy were positive in 58%.

158 For patients with negative results on somatostatin receptor scintigraphy, guidelines about the

159 modalities including endoscopic ultrasound, somatostatin receptor scintigraphy, long-acting octreoti

160 uted tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, whole-body positron

161 1% for MRI, 62% for angiography, and 92% for somatostatin receptor scintigraphy.

162 In Zollinger-Ellison syndrome, somatostatin-receptor scintigraphy provides an excellent

163 Their infection was specific to target somatostatin receptors, since a synthetic somatostatin p

164 h (18)F-fluorodihydroxyphenyl-l-alanine PET, somatostatin receptor SPECT, CT, or MR imaging.

165 use enhances the efficiency of radiolabeled somatostatin receptor (sst) imaging.

166 cal and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrat

167 ested for binding affinity at the five human somatostatin receptors (sst(1)(-)(5)).

168 for their binding affinity to the five human somatostatin receptors (sst(1-5)), as well as for their

169 feration of human aortic SMCs via binding to somatostatin receptors (sst2 and sst5) and ghrelin recep

170 The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cance

171 ptor radionuclide therapy using radiolabeled somatostatin receptor (SSTR) agonists are successfully u

172 have shown enhanced tumor targeting by novel somatostatin receptor (SSTR) antagonists compared with c

173 Radiolabeled somatostatin receptor (SSTR) antagonists have shown in v

174 avidity to somatostatin analogues suggested somatostatin receptor (SSTR) expression in VHL-HBs, offe

175 Somatostatin receptor (SSTR) imaging is widely used for

176 Somatostatin receptor (SSTR) ligands inhibit GH release,

177 Somatostatin receptor (sstr) scintigraphy for imaging an

178 Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation

179 te the signaling events mediated by specific somatostatin receptor (SSTR) subtypes, we expressed SSTR

180 indium-111 complex, is already approved for somatostatin receptor (SSTR)-expressing tumor imaging in

181 Somatostatin receptors (SSTR) are highly expressed in we

182 In vitro somatostatin receptors (SSTR)-binding affinities of P587

183 Interestingly, somatostatin receptor (sstr1) expression was increased b

184 ell as by their binding affinities to cloned somatostatin receptors (SSTR1-5).

185 n, Cebpd), as well as neuropeptide signaling somatostatin receptor (Sstr2).

186 The method's application to somatostatin receptor SSTR5 (no experimental structure a

187 These rare human tumors often express somatostatin receptors (SSTRs) and thus are clinically r

188 ely, for PRRT and PET examinations targeting somatostatin receptors (SSTRs) in patients affected by n

189 xamined the expression of mRNAs for the five somatostatin receptors (SSTRs) in the caudate putamen of

190 Expression of somatostatin receptors (SSTRs) was assessed by reverse-t

191 reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a s

192 Because of the presence of cell membrane somatostatin receptors (SSTRs), many neuroendocrine tumo

193 etermined to identify sterically constrained somatostatin receptor subtype 1 (sst(1)) selective scaff

194 has high affinity and selectivity for human somatostatin receptor subtype 1 (sst1).

195 The human somatostatin receptor subtype 2 (hSSTr2)-68Ga-DOTATOC re

196 of somatostatin receptor subtype 5 (SST5) to somatostatin receptor subtype 2 (SST2) action in these c

197 Somatostatin receptor subtype 2 (sst2) agonists inhibit

198 is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are b

199 h bind selectively and with high affinity to somatostatin receptor subtype 2 (sst2) have been synthes

200 oendocrine tumors, target the high levels of somatostatin receptor subtype 2 (SSTR1; alias sst2) expr

201 Somatostatin receptor subtype 2 (SSTR2) has been used as

202 Human somatostatin receptor subtype 2 (SSTR2) has been used fo

203 E2A-Y3-TATE (64Cu-[2]) had high affinity for somatostatin receptor subtype 2 (SSTr2) in A427-7 cells.

204 Somatostatin receptor subtype 2 (sstr2) is a G-protein-c

205 Recently, the somatostatin receptor subtype 2 (SSTR2) selective antago

206 somatostatin with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in s

207 ormed a screen for drugs that upregulate the somatostatin receptor subtype 2 (sstr2).

208 rains engineered to functionally express the somatostatin receptor subtype 2 and exhibit agonist-depe

209 strategy, induction of high levels of human somatostatin receptor subtype 2 expression and selective

210 The somatostatin receptor subtype 2 is expressed on macropha

211 AMBF3-TATE bound the somatostatin receptor subtype 2 with high affinity (inhi

212 ibited unexpectedly high binding affinity to somatostatin receptor subtype 2, and showed excellent ph

213 Visualization of somatostatin receptor subtype 2, for oncologic purposes,

214 aging agent that binds with high affinity to somatostatin receptor subtype 2, found on many human can

215 ed with Cu and (64)Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 c

216 n to have the highest affinity yet found for somatostatin receptor subtype 2.

217 Somatostatin receptor subtype 2A (sst2A) mediates many o

218 The somatostatin receptor subtype 3 (Sstr3) is selectively t

219 To assess the contribution of somatostatin receptor subtype 5 (SST5) to somatostatin r

220 r neuronal compartments, one of which is the somatostatin receptor subtype SST(3).

221 (HSVtk) for molecular chemotherapy and human somatostatin receptor subtype-2 (hSSTR2) for indirect im

222 Resected carotid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemic

223 ium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET trace

224 Somatostatin receptor subtype-4 (SSTR4) agonists have be

225 We have isolated and sequenced the mouse somatostatin receptor subtype-4-encoding gene (mSSTR4).

226 ding profile, with high binding affinity for somatostatin-receptor subtype 5.

227 structure of octreotide that binds to three somatostatin receptor subtypes (sst 2/3/5) with signific

228 The study of the five somatostatin receptor subtypes (SSTx, where x is the sub

229 (68)Ga-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst2,3,5).

230 All somatostatin receptor subtypes are coupled to inhibition

231 Thus, by expressing individual somatostatin receptor subtypes in pituitary cells, we ha

232 hin intracellular domain 3 are shared by the somatostatin receptor subtypes SSTR1, -3, and -4, which

233 axis, we showed that rat hepatocytes express somatostatin receptor subtypes-2 and -3 and that IGF-I m

234 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has been used cli

235 We evaluated whether somatostatin receptor-targeted radionuclide therapy with

236 s when designing metal-peptide complexes for somatostatin receptor targeting.

237 tly higher affinity (IC50 = 0.15 nM) for the somatostatin receptor than the anti diastereomer (IC50 =

238 Carcinoid tumors have high numbers of somatostatin receptors that allow scintigraphic imaging

239 cate that there are multiple elements in the somatostatin receptors that can determine the binding af

240 alt-labeled octreotide analogs targeting the somatostatin receptor to identify promising candidates f

241 lity of peptide MIII-4 as well as endogenous somatostatin receptors to activate endogenous G(i) and t

242 2) (SRIF numbering), at the five known human somatostatin receptors transfected into and stably expre

243 Selective antagonism of somatostatin receptor type 2 (SSTR2) normalizes glucagon

244 ECTIVE This study evaluated the influence of somatostatin receptor type 2 (SSTR2) polymorphisms on me

245 ly to locate tumors overexpressing primarily somatostatin receptor type 2 (SSTR2).

246 Thus, a selective somatostatin receptor type 2 antagonist (SSTR2a) should

247 orally with an adenovirus containing a human somatostatin receptor type 2 gene chimera (Ad-HA-SSTR2)

248 emonstrate a lack of ciliary localization of somatostatin receptor type 3 (Sstr3) and melanin-concent

249 The sulfonylurea receptor (Sur) and somatostatin receptor type 5 (SSTR5) play an integral ro

250 Little information is available about the somatostatin receptor types which may be involved in med

251 stern blotting revealed the presence of five somatostatin receptor types, sst1, sst2, sst3, sst4 and

252 nity of nonradioactive (185/187)Re-P2045 for somatostatin receptors was compared in human NCI-H69 and

253 -specific desensitization of the M(1)Ach and somatostatin receptors was significantly attenuated in a

254 Nonpeptide agonists of each of the five somatostatin receptors were identified in combinatorial

255 metal cyclization, as well as binding to the somatostatin receptor, were investigated.

256 e physiological roles played by type 3 and 5 somatostatin receptors which are still far from being fu

257 The somatostatin receptor, which is overexpressed by many ne

258 of [111In-DTPA-DPhe1]octreotide scanning for somatostatin receptors, which these tumors characteristi